Detalhe da pesquisa
1.
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 384(9): 829-841, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33657295
2.
KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer.
Future Oncol
; 19(37): 2445-2452, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37701986
3.
Succinate Dehydrogenase-Deficient Renal Cancer Featuring Fructose-1,6-Biphosphatase Loss, Pyruvate Kinase M2 Overexpression, and SWI/SNF Chromatin Remodeling Complex Aberrations: A Rare Case Report.
Oncologist
; 26(9): e1652-e1655, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34003534
4.
External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model.
Int J Clin Oncol
; 24(5): 526-532, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30604160
5.
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
Lancet Oncol
; 16(15): 1473-1482, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26482279
6.
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Lancet Oncol
; 15(3): 286-96, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24556040
7.
Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence.
Clin Genitourin Cancer
; 22(1): 84-97, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38101983
8.
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
Eur Urol
; 85(3): 229-238, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37778952
9.
Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib.
Kidney Blood Press Res
; 35(6): 468-76, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22688785
10.
Real-world Experience of Cabozantinib as Second- or Subsequent Line Treatment in Patients With Metastatic Renal Cell Carcinoma: Data From the Polish Managed Access Program.
Clin Genitourin Cancer
; 17(3): e556-e564, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30987807
11.
Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis.
Endokrynol Pol
; 70(4): 313-317, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30843182
12.
New therapeutic options in systemic treatment of advanced cutaneous melanoma.
Expert Opin Investig Drugs
; 22(2): 181-90, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23215674
13.
Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.
J Cancer Res Clin Oncol
; 136(3): 371-8, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19711099
14.
Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.
Cancer
; 115(1): 61-7, 2009 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19051290